Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Critical Medicines List To Be Ready ‘Within Days’

Executive Summary

Members of the European Parliament were told that once the list was out, work would begin on identifying the products most vulnerable to supply chain problems.

You may also be interested in...

Paracetamol Included In EU List Of Critical Medicines

Paracetamol makes it onto the European Commission's first ever EU-level list of critical medicines whose continuity of supply is a priority and for which “shortages should be avoided.”

EU Publishes First Critical Medicines List In Drive To Tackle Shortages

The list contains more than 200 active substances and includes rare disease drugs and vaccines.

EU Floats Raft Of Plans To Tackle ‘Critical’ Drug Shortages

The European Commission says the collective actions it is proposing should allow it to work more closely with the pharmaceutical industry and help EU member states improve the security of medicines supply.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts